Participants in the Abacus study achieved an average weight reduction of 21% after one year of treatment. More notably, those same individuals maintained an 18% weight loss at the 24-month mark, a full year after they had ceased using GLP-1 anti-obesity medication. The organization tracked these outcomes using objective data from connected scales rather than relying on self-reported metrics.

Dr. David K. Ahern emphasized that while the industry excels at measuring active treatment phases, the post-treatment horizon has remained largely opaque. The Abacus model suggests that sustainable results require a synthesis of pharmacological intervention and rigorous behavioral reinforcement. By focusing on consistent habits like self-monitoring and balanced nutrition during and after medication, the program addresses the common clinical challenge of rapid weight regain. These findings offer employers and health plans a benchmark for managing obesity treatment costs while prioritizing long-term patient health outcomes.